HealthExec features PAN research that finds half of patients face drug coverage denials
During our transition, where to find information about:
- Our merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
A national poll from the PAN Foundation’s Center for Patient Research that finds half of patients face chronic and rare condition drug denials from their health insurance plans was featured in HealthExec.
About half of commercially insured patients reported in the survey that their insurance plan referred them to work with an external company to obtain their specialty medications. Of those patients who did opt to work with the external company, about a third experienced a delay of one to six months in their treatment.
“It is deeply troubling that a significant number of people with a chronic or rare condition report a loss of health insurance coverage for a medically necessary medication and are being referred to work with external companies to gain access to their treatment, often causing significant delays,” quoted Amy Niles, chief mission officer at PAN, in the HealthExec article.